The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials

Journal of Thoracic Oncology - United States
doi 10.1097/jto.0000000000000667
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Redefining Treatment Paradigms in First-Line Advanced Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

Cost-Effectiveness of First-Line Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer Unsuitable for Chemotherapy

BMJ Open
Medicine
2015English

A Systematic Review of the Clinical Effectiveness of First-Line Chemotherapy for Adult Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Thorax
PulmonaryRespiratory Medicine
2015English

Phase II Study of Gemcitabine Plus Oxaliplatin as First-Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
2005English

Taxotere: Clinical Trials in Non‐Small Cell Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
1998English

Bevacizumab Combination Chemotherapy in Clinical Practice for Advanced Non-Squamous Non-Small Cell Lung Cancer

Japanese Journal of Lung Cancer
OncologyRespiratory MedicinePulmonary
2013English

Palliative Chemotherapy for Advanced Non-Small Cell Lung Cancer

BMJ
1994English

Cost-Effectiveness of First-Line Therapy for Advanced Non-Small Cell Lung Cancer (Nsclc)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systemic Review

PLoS ONE
Multidisciplinary
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy